InDex Pharmaceuticals Holding AB (publ) announced that the positive results from the pharmacokinetic (PK) study with cobitolimod in patients with moderate to severe ulcerative colitis will be presented at one of the leading gastroenterology conferences, the United European Gastroenterology Week (UEGW). The abstract was selected as one of the best abstracts for poster presentation and is therefore also chosen to be presented orally in one of the moderated poster sessions. Results from the PK study included PK data from 7 patients with moderate to severe ulcerative colitis treated with doses of 500 mg of cobitolimod administered rectally.

The systemic uptake of cobitolimod was limited both for patients with active disease and in clinical remission, with the majority of patients having undetectable levels of cobitolimod in the plasma after 8 hours. Even though it was a small-scale open-label study, it was encouraging that 4 out of 7 patients achieved clinical remission at week 6 after receiving two doses of 500 mg cobitolimod. In line with previous studies, cobitolimod was well tolerated and no serious adverse events were reported in the study.